Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

IDH2 R172 mutation is associated with improved survival in IDH-mutated AML/MDS patients undergoing allogeneic stem cell transplantation: A geth-TC multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAna Pérez GonzálezMGManuel GuerreiroMMM. Montaner

Discussion

Loading...

Member takes

Overview

Observational analysis reveals improved survival and lower relapse in IDH2 R172 AML/MDS patients post-transplant, highlighting clinical implications.

Key Points

  • IDH2 R172 mutation predicts better overall survival in AML/MDS patients post-transplant.
  • In this multicenter study, 93% of IDH2 R172 patients achieved 1-year survival compared to 74% in others.
  • The analysis utilized multivariable models to examine survival outcomes and relapse rates in transplant settings.
  • Findings indicate the potential for better risk stratification in transplant decision-making for AML/MDS patients.

Cite This Study

González et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b9https://doi.org/10.1182/blood-2025-6082
View Full Paper
Ask AI
Bookmark
Share